Rep. Kevin Hern Sells Off Shares of Novo Nordisk A/S (NYSE:NVO)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Trading Down 1.3%

Shares of NYSE NVO traded down $0.49 during trading on Tuesday, reaching $38.22. The company had a trading volume of 5,846,501 shares, compared to its average volume of 17,087,889. The stock has a market cap of $170.64 billion, a P/E ratio of 9.33, a PEG ratio of 1.27 and a beta of 0.74. The company’s fifty day moving average price is $45.51 and its 200-day moving average price is $43.87. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. As a group, research analysts expect that Novo Nordisk A/S will post 3.54 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a $0.5786 dividend. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio is presently 20.05%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC boosted its position in shares of Novo Nordisk A/S by 4.7% in the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after purchasing an additional 242 shares during the period. Carson Advisory Inc. increased its stake in Novo Nordisk A/S by 2.2% in the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock worth $453,000 after buying an additional 268 shares in the last quarter. Bradley Foster & Sargent Inc. CT grew its holdings in Novo Nordisk A/S by 0.6% during the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after buying an additional 272 shares in the last quarter. Arlington Partners LLC boosted its position in shares of Novo Nordisk A/S by 4.4% during the second quarter. Arlington Partners LLC now owns 6,777 shares of the company’s stock worth $325,000 after acquiring an additional 283 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in Novo Nordisk A/S by 13.1% during the second quarter. Parkside Financial Bank & Trust now owns 2,436 shares of the company’s stock valued at $117,000 after buying an additional 283 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: A real-world analysis presented at EASD found that adults with type 2 diabetes who escalated Ozempic (semaglutide) to 2 mg had a statistically significant 6% lower risk of major cardiovascular events than patients who switched to Eli Lilly’s Mounjaro (tirzepatide). The result could strengthen Ozempic’s clinical and commercial positioning, although the evidence is retrospective rather than from a randomized head-to-head trial. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Novo agreed to license global rights to Hengrui Pharma’s phase 1-ready oral GLP-1/GIP drug HRS-1596. The agreement includes $300 million upfront and potential payments of up to $2.6 billion, expanding Novo’s oral obesity and diabetes pipeline and potentially supporting a future once-weekly treatment. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: Phase 3 REIMAGINE 5 data showed the lower-dose CagriSema combination produced approximately 12.4% weight loss after 60 weeks in adults with type 2 diabetes, giving Novo a more competitive result against Lilly’s tirzepatide-based therapies. Novo is also pursuing Nanexa’s drug-delivery technology, which could enable longer-interval dosing across several cardiometabolic programs. Novo Nordisk Just Beat Lilly in a Trial
• Positive Sentiment: The company’s share-repurchase program, part of a DKK 15 billion authorization over 12 months, may provide technical support and signal management’s confidence in long-term value. Novo Nordisk share repurchase programme
• Neutral Sentiment: Analyst coverage continues to frame Novo and Pfizer as having different growth profiles, with portfolio diversification, pipelines, and near-term execution risks determining which company offers better prospects. Citi maintained a DKK 310 price target while the stock traded around DKK 253. Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
• Negative Sentiment: Eli Lilly countered Novo’s cardiovascular news by saying its oral obesity drug Foundayo delivered greater weight loss and better blood-sugar control than a higher-dose Ozempic pill in an analysis of existing studies. The competing claims reinforce concerns about Lilly’s growing advantage in the obesity market. Lilly touts Foundayo advantage over Novo’s Ozempic pill
• Negative Sentiment: Investors continue to question whether Novo can develop a “second act” as Lilly intensifies competition and several pipeline assets remain early stage. Roche’s positive obesity-drug data add another potential challenger to an already crowded market. Roche’s Latest Obesity Drug Results

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $64.94.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.